The drug has three labeled indications: RA, psoriatic arthritis (PsA) and ulcerative colitis (UC), and acts by inhibiting JAK1, JAK2, JAK3 and, to a lesser extent, TYK2. Here, JAK3 is linked to rheumatoid arthritis.